Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + D-TACE + lenvatinib versus D-TACE + lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus
ChiCTR2300073121Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab and lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Objective response rate. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
camrelizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300073121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073121.